PRITHVIRAJ BOSE to Fusion Proteins, bcr-abl
This is a "connection" page, showing publications PRITHVIRAJ BOSE has written about Fusion Proteins, bcr-abl.
Connection Strength
0.418
-
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1657-67.
Score: 0.281
-
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
Score: 0.108
-
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
Score: 0.030